Huaren Health: Plans to acquire 46.01% equity of Yangzu Huimin for 133 million yuan
Huaren Health announced that the company plans to purchase 46.01% equity of Yangzu Huimin for RMB 133 million, 46.01% equity of Haihua Pharmaceutical for RMB 125 million, and 70.01% equity of Tonglu Yishengtang for RMB 68.2598 million. After the completion of this transaction, the target companies will be included in the company's consolidated financial statements. The company plans to use its own funds and change part of the fundraising purposes for payment. If the review for changing the fundraising purposes is not approved, all payments will be made using its own funds
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments